# A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors

> **NCT05773937** · PHASE1 · RECRUITING · sponsor: **Mabwell (Shanghai) Bioscience Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Advanced Malignant Solid Tumors

## Interventions

- **DRUG:** 9MW2821

## Key facts

- **NCT ID:** NCT05773937
- **Lead sponsor:** Mabwell (Shanghai) Bioscience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-21
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05773937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05773937, "A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05773937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*